

Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome



Stephen A. Clarkson, MD^{a,*}, Brittain Heindl, MD^a, Anping Cai, MD^b, Mark Beasley, PhD^c, Chris Dillon, MD^b, Nita Limdi, PharmD, PhD^b, and Todd M. Brown, MD, MSPH^a

Major adverse cardiac event (MACE) and bleeding risks following percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) are not well defined in individuals with heart failure (HF). We followed 1,145 individuals in the Pharmacogenomic Resource to improve Medication Effectiveness Genotype Guided Antiplatelet Therapy cohort for MACE and bleeding events following PCI for ACS. We constructed Cox proportional hazards models to compare MACE and bleeding in those with versus without HF, adjusting for sociodemographics, comorbidities, and medications. We also determined predictors of MACE and bleeding events in both groups. 370 (32%) individuals did and 775 (68%) did not have HF prior to PCI. Mean age was 61.7 ± 12.2 years, 31% were female, and 24% were African American. After a median follow-up of 0.78 years, individuals with HF had higher rates of MACE compared to those without HF (48 vs. 24 events per 100 person years) which remained significant after multivariable adjustment (hazard ratio [HR] 1.31, 95% confidence interval [CI] 1.00 to 1.72). Similarly, bleeding was higher in those with versus without HF (22 vs. 11 events per 100 person years), although this was no longer statistically significant after multivariable adjustment (HR 1.29, 95% CI 0.86 to 1.93). Diabetes and peripheral vascular disease were predictors of MACE, and end-stage renal disease was a predictor of bleeding among participants with HF. MACE risk is higher in individuals with versus without HF following PCI for ACS. However, the risk of bleeding, especially among those with end-stage renal disease, must be considered when determining post-PCI anticoagulant strategies. © 2021 Elsevier Inc. All rights reserved. (Am J Cardiol 2021;148:1–7)

Ischemic heart disease is a leading cause of death among those living in the United States¹ and is associated with both an almost 8-fold increased risk of developing heart failure (HF).² It is an important cause of HF hospitalization and death, as patients with HF and coronary artery disease (CAD) have a higher 10 year mortality than HF patients without concomitant CAD.^{3,4} HF patients who experience an ischemic event have an almost 3-fold increased risk of recurrent ischemic events as compared to HF patients who do not experience an event⁵ and preventing these events has been the rationale for long-term dual-antiplatelet therapy

(DAPT) regimens.⁶ Major bleeding is the most common complication of DAPT therapy with a 3 to 4 times higher risk of all-cause mortality,⁷ an increase in the rate of in-hospital mortality, and 30-day major adverse cardiac events (MACE).⁸ Understanding the predictors of MACE and major bleeding in individuals receiving PCI for ACS is imperative to mitigate the risks associated with PCI and the medical therapy that follows. MACE events are most often associated with traditional cardiovascular risk factors; however, prior history of HF is an often under-represented cohort in the ACS literature.⁹ Advanced age, female sex, and renal insufficiency have been associated with an increased risk of bleeding while taking DAPT,¹⁰ however, the risk of bleeding while on DAPT in patients with HF is unknown. In this study, we sought to compare the risk and characterize predictors of MACE and major bleeding events for patients with and without HF.

Methods

The Pharmacogenomic Resource to improve Medication Effectiveness Genotype Guided Antiplatelet Therapy is a prospective cohort study conducted under the approval of the Institutional Review Board of the University of Alabama at Birmingham (UAB). Patients eligible for enrollment included those who underwent PCI and were subsequently admitted to UAB Hospital. As a component of the study genetic data was obtained and thus participants must be willing and able to provide consent. A total of 1,596 participants were enrolled between April 2014 and

^aDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; ^bDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama; and ^cDepartment of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama. Manuscript received December 7, 2020; revised manuscript received and accepted February 23, 2021.

Relationships with Industry and Other Entities: None.

Funding: Supported in part by UAB's Health Service Foundations' General Endowment Fund and Hugh Kaul Personalized Medicine Institute and National Heart Lung and Blood Institute (RO1HL092173; K24HL133373) and the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR000165). Dr. Clarkson is supported under National Institutes of Health (NIH) grant T32 HL129948. The project was funded by the 3 mechanisms listed, the R grant, the K grant, and the U grant.

See page 6 for disclosure information.

*Corresponding author: Tel: (205) 934-0820; fax: (205) 975-8568.

E-mail address: sclarkson@uabmc.edu (S.A. Clarkson).

November 2019. Of these, 1,145 participants received PCI for an ACS indication and were included in this analysis. ACS, defined as unstable angina, non-ST segment elevation MI, or ST segment elevation MI, was determined by a fellow in the cardiovascular disease fellowship under direct supervision of a board-certified cardiology faculty.

After enrollment, a trained coordinator completed a structured case report form. Demographic information was abstracted from the medical record, including each participant's age, sex, race, past medical history, and cardiovascular risk factors. An interview was conducted to document the participant's health insurance status, level of education, smoking history, current employment, home medications, medication adherence, physical activity, marital status, and home ownership.

Procedural characteristics were obtained at the time of PCI. These included indication for PCI, vital signs, access site, contrast volume, number of obstructed coronary arteries, type of stents placed, and number of stents placed. Information about the severity of each participant's coronary disease was obtained via chart abstraction, with obstructed coronary disease classified as $>70\%$ stenosis. Medications given during and after the PCI procedure, including antiplatelet therapy, were documented.

Participants were classified based on the presence or absence of HF prior to undergoing PCI. HF was defined as having an echocardiogram showing a left ventricular ejection fraction of $<50\%$ prior to PCI, if there was no EF documented, then HF was defined as a medical history of HF or a brain natriuretic peptide level of ≥ 400 mg/dl prior to PCI.¹¹

Participants were followed for up to 1 year after PCI. UAB medical records were reviewed and changes in medication use, laboratory parameters, hospitalizations, MACE, and major hemorrhage (HEM) during follow-up were documented. We requested physical and/or electronic medical records from participants' primary care physicians, cardiologists, and/or outside hospital records in case of hospitalization. This was done to ensure encounters outside of the UAB health system were obtained and recorded. All potential MACE and HEM events were adjudicated by expert clinician adjudicators after review of all available medical records.

MACE events were defined as the composite of death (both cardiovascular and non-cardiovascular), non-fatal myocardial infarction (MI), non-fatal ischemic stroke or transient ischemic attack (TIA), and stent thrombosis. MI was diagnosed based on an increase in the cardiac troponin above the 99th percentile upper reference limit in addition to ischemic symptoms or new electrocardiographic findings suggestive of myocardial ischemia. Stent thrombosis was defined as evidence of thrombosis on invasive angiogram. Stroke and TIA were diagnosed based on the presence of a focal neurologic deficit plus imaging evidence of new focal lesion, or new focal deficit defined as TIA by a neurologist. Death was determined through both the inpatient and outpatient medical record.

HEM events were defined as a composite of intracranial HEM, gastrointestinal (GI), or other HEM that resulted in significant hemodynamic compromise requiring treatment, as defined by the Global Utilization of Streptokinase and

Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria.¹² The GUSTO criteria classified intracerebral HEM and hemodynamic compromise as evidence of severe or life-threatening bleeding, with the identifier of major bleeding being hemodynamic compromise.

The data were summarized using absolute number and percent of total for categorical variables and mean and standard deviation for continuous variables. To compare differences between groups, we used *t*-tests for continuous variables and χ^2 -tests for categorical variables. Next, we calculated incidence rates for MACE and major bleeding events in those with and without HF and compared these rates in those with versus without HF using incident rate ratios (IRR) and 95% confidence intervals (CI).

In order to determine the independent association of HF status with MACE and major bleeding events, we constructed Cox proportional hazards models to calculate hazard ratios (HR) and 95% CI for participants with versus without HF. All covariates listed in Table 1 were added to the model if they varied by HF status in bivariate analyses using a *p* value of <0.05 . In model 1, we added demographics, including age, black race, female sex as well as past medical history, including hypertension, diabetes mellitus, atrial fibrillation, CAD, end-stage renal disease (ESRD), and peripheral vascular disease (PVD), insurance status, and alcohol use. Then, in model 2, we included components of the first model plus medications prescribed at discharge, including DAPT (aspirin with clopidogrel or aspirin with ticagrelor), calcium-channel blocker, aldosterone inhibitor, diuretics, and oral anticoagulation (warfarin, rivaroxaban, or apixaban). Finally, we constructed Cox proportional hazards models, separately in those with and without HF, to determine which factors predicted MACE and major bleeding events. Factors included in the multivariable model were those known to influence MACE and bleeding (age,¹³ race,¹⁴ gender,¹⁵ DAPT therapy^{6,16}), in addition to factors listed in Table 1 that were associated with the outcome of interest in univariate analyses with a *p*-value <0.20 .¹⁷ All analyses were performed using SAS version 9.4.

Results

The baseline characteristics, demographic information, and medications prescribed at discharge for our study population are shown in Table 1. Of the 1,145 participants with ACS, 370 had evidence of HF before PCI. The HF and non-HF populations did not differ in terms of female gender and black race. Participants with HF had a lower mean ejection fraction, lower mean systolic blood pressure, and higher mean brain natriuretic peptide levels than those without HF. In addition, as compared to those without HF, participants with HF had a higher prevalence of hypertension, diabetes mellitus, atrial fibrillation, CAD, ESRD, and PVD. However, participants without HF were more likely to consume alcohol than those with HF. In terms of medications, participants with and without HF were similarly likely to receive aspirin at discharge, although individuals with HF were more likely to receive clopidogrel and less likely to receive ticagrelor than those without HF.

Table 1.

Demographics, Comorbidities, and Medications by heart failure status among individuals undergoing percutaneous coronary interventions for acute coronary syndromes in the pharmacogenomic resource to improve medication effectiveness genotype guided antiplatelet therapy cohort, April 2014 to November 2019

Variable	Heart Failure		p Value
	Yes (N = 370)	No (N = 775)	
Age (years)	62.7 ± 11.82	61.0 ± 12.29	0.029
Women	109 (29%)	250 (32%)	0.340
Black Race	94 (25%)	181 (23%)	0.448
Left Ventricular Ejection Fraction (%)	36.9 ± 9.4	58.0 ± 5.7	<0.001
Systolic Blood Pressure (mm Hg)	138.6 ± 22	144.1 ± 24.3	<0.001
Diastolic Blood Pressure (mm Hg)	83.2 ± 14.4	84.6 ± 15.2	0.138
Brain Natriuretic Peptide (pg/dl)	1022.9 ± 1902.1	294.3 ± 723.3	<0.001
Hypertension	326 (88%)	648 (84%)	0.046
Dyslipidemia	271 (73%)	546 (70%)	0.329
Diabetes Mellitus	293 (79%)	189 (24%)	<0.001
Atrial Fibrillation	66 (18%)	71 (9%)	<0.001
Coronary Heart Disease	279 (75%)	404 (52%)	<0.001
Chronic Kidney Disease	89 (24%)	112 (14%)	<0.001
End-Stage Renal Disease	32 (9%)	21 (3%)	<0.001
Peripheral Vascular Disease	58 (16%)	74 (10%)	0.002
Insurance status			
Private	139 (38%)	373 (48%)	<0.001
Medicare	170 (46%)	258 (33%)	<0.001
Medicaid	144 (39%)	61 (8%)	<0.001
Education level			
<High-School	199 (54%)	404 (52%)	0.244
>High-School	142 (38%)	311 (40%)	0.571
Alcohol Use	92 (25%)	253 (33%)	0.006
Smoker	104 (28%)	223 (29%)	0.690
Income <\$50,000	148 (40%)	301 (39%)	0.385
Medications at discharge			
Aspirin	352 (95%)	753 (97%)	0.183
DAPT	336 (93%)	732 (96%)	0.046
DAPT using Clopidogrel	233 (63%)	454 (59%)	0.044
DAPT using Ticagrelor	103 (28%)	278 (36%)	0.009
Statin Therapy	336 (91%)	710 (92%)	0.922
Beta-Blocker	314 (85%)	652 (84%)	0.454
Calcium Channel Blocker	61 (16%)	192 (24%)	0.002
ACEi/ARB	187 (52%)	404 (53%)	0.737
Spironolactone	51 (14%)	40 (5%)	<0.001
Diuretic	183 (51%)	220 (29%)	<0.001
Insulin at Discharge	93 (26%)	127 (16%)	<0.001
Oral Anticoagulant	57 (16%)	47 (6%)	<0.001
Warfarin	36 (10%)	28 (4%)	<0.001
Apixaban	21 (6%)	19 (3%)	0.005

ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CHF = congestive heart failure; DAPT = dual anti-platelet therapy.

All values expressed as mean ± standard deviation or number (percent).

Diuretics: indapamide, methazolamide, metolazone, acetazolamide, bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, triamterene, chlorothiazide, or chlorthalidone.

Oral Anticoagulation: warfarin, apixaban

The rates of both MACE and bleeding events over a median follow-up of 0.78 years for individuals with and without HF are shown in Table 2. Participants with HF were nearly twice as likely to have MACE than participants without HF. This unadjusted increased risk was related to an increase in all-cause mortality and non-fatal myocardial infarction in those with as compared to without HF. The increased risk for MACE and all-cause mortality remained significant after multivariable adjustment.

Participants with HF were also almost twice as likely to have major bleeding events than participants without HF. This unadjusted risk was driven mainly by differences in GI and other bleeding events, with a 2 times higher risk of GI bleeding for participants with as compared to without HF. Although this increased bleeding risk remained significant when adjusting for medical history, it was no longer statistically significant after adjustment for medications prescribed at discharge.

Table 2.

Major adverse cardiovascular event and major bleeding event rates by heart failure status among individuals undergoing percutaneous coronary interventions for acute coronary syndromes in the pharmacogenomic resource to improve medication effectiveness genotype guided antiplatelet therapy cohort, April 2014 to November 2019

Follow-up (years)	Heart Failure				IRR (95% CI)	Model 1HR (95% CI) [†]	Model 2HR (95% CI) [‡]
	Yes (n = 370)		No (n = 775)				
	N	Incidence rate*	N	Incidence rate*			
	264.96		627.54				
MACE	126	47.8	150	23.9	1.99 (1.57-2.52)	1.44 (1.11-1.86)	1.31 (1.00-1.72)
All-Cause Mortality	43	16.2	37	5.9	2.75 (1.77-4.27)	1.93 (1.19-3.13)	1.76 (1.04-2.99)
Non-Fatal Myocardial Infarction	82	31.0	99	15.8	1.96 (1.46-2.63)	1.39 (1.01-1.90)	1.29 (0.93-1.81)
Non-Fatal Ischemic Stroke/TIA	9	3.4	20	3.2	1.07 (0.49-2.34)		
Stent Thrombosis	8	3.0	11	1.8	1.72 (0.69-4.28)		
Major Bleeds	58	21.9	70	11.2	1.96 (1.39-2.78)	1.73 (1.89-2.52)	1.29 (0.86-1.93)
Intracranial	3	1.1	5	0.8	1.42 (0.34-5.95)		
Gastrointestinal	25	9.4	27	4.3	2.19 (1.27-3.78)	2.06 (1.14-3.73)	1.70 (0.89-3.26)
Other	30	11.3	38	6.1	1.87 (1.16-3.02)	1.60 (0.95-2.68)	1.17 (0.68-2.03)

CHF = congestive heart failure; CI = confidence interval; HR = hazard ratio; IRR = incidence rate ratio; MACE = major adverse cardiovascular event; N = number; TIA = transient ischemic attack.

* Incidence rate per 100 patient years.

[†] Adjusted for age, female sex, black race, hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, end-stage renal disease, peripheral vascular disease, insurance status, and alcohol use.

[‡] Adjusted for covariates included in model 1 plus the following medications prescribed at discharge: DAPT (dual-antiplatelet therapy), calcium-channel blockers, aldosterone inhibitors, diuretics, and anticoagulation (warfarin or apixaban).

The predictors of MACE and major bleeding in individuals with and without HF are shown in Table 3. Among those with HF, prior history of CAD, diabetes mellitus, ESRD, PVD, private insurance, having less than a high school education, use of diuretics, calcium channel blockers, ACE-inhibitors, warfarin, and statins were associated with MACE in univariate analyses. Of these, diabetes remained statistically significant after multivariable adjustment. PVD trended towards elevated risk, however, was not statistically significant. For participants without HF, black race, hypertension, atrial fibrillation, diabetes, ESRD, PVD, private insurance, ACE inhibitor, aldosterone antagonist, insulin, warfarin, and diuretic use were associated with MACE in univariate analyses. Black race, ESRD, PVD,

and diuretic use remained statistically significant after multivariable adjustment. For major bleeding, ESRD was associated with a 4 to 5 times higher risk of major bleeding in those with and without HF and remained a statistically significant predictor of bleeding after multivariable adjustment in both populations.

Discussion

In this analysis, as compared to those without HF, participants with a history of HF who underwent PCI for the treatment of ACS were more likely to experience MACE and major bleeding events over 1 year of follow-up. The risk of MACE remained significant after multivariable

Table 3.

Independent predictors of major adverse cardiovascular events and major bleeding events by heart failure status among individuals undergoing percutaneous coronary interventions for acute coronary syndromes in the pharmacogenomic resource to improve medication effectiveness genotype guided antiplatelet therapy cohort, April 2014 to November 2019

	Heart failure			
	Yes (N = 370)		No (N = 775)	
	UnivariateHR (95% CI)	MultivariableHR (95% CI)	UnivariateHR (95% CI)	MultivariableHR (95% CI)
MACE				
Black Race	1.24 (0.77-2.00)	1.27 (0.59-2.77)	2.10 (1.35-3.25)	2.07 (1.32-3.22)
Diabetes Mellitus	1.70 (1.09-2.66)	2.55 (1.04-6.25)	1.93 (1.25-2.96)	1.32 (0.77-2.29)
ESRD	3.01 (1.93-4.95)	2.36 (0.55-10.11)	3.59 (1.64-7.85)	2.67 (1.10-6.25)
PVD	1.90 (1.18-3.07)	2.34 (0.92-5.95)	2.86 (1.66-4.91)	1.95 (1.07-3.57)
Alcohol Use	0.91 (0.50-1.63)	*	0.42 (0.25-0.73)	0.55 (0.33-0.90)
Diuretic Use	1.46 (0.92-2.31)	1.31 (0.46-3.69)	2.07 (1.34-3.20)	1.63 (1.00-2.67)
Major Bleeding				
ESRD	4.31 (1.88-9.89)	3.27 (1.32-8.12)	5.42 (2.62-11.23)	4.17 (1.37-12.74)

Abbreviations: CHF = congestive heart failure; CI = confidence interval; ESRD = end stage renal disease; HR = hazard ratio; MACE = major adverse cardiovascular event; PVD = peripheral vascular disease.

* Represents a variable that did not reach a p value of <0.20 in univariate analysis and was not included in the multivariable model.

adjustment, although the risk of major bleeding was no longer significant after adjustment for medication use. These data suggest that there is an inherent risk for MACE and major bleeding complications following PCI in those with HF and this inherent risk should be considered when managing these individuals in clinical practice. Additionally, predictors of MACE and bleeding outcomes differed in those with and without HF, highlighting the importance of patient specific characteristics when evaluating secondary prevention measures for individuals with ACS and further magnifying the inherent risk associated with HF for both outcomes.

In addition to revascularization, the management of patients following ACS focuses on the prevention of future ischemic events and the hallmark of this prevention strategy is the use of dual anti-platelet therapy (DAPT).⁶ After an event, there is a Class 1 indication for a minimum time of 6 to 12 months, with discretion for longer use given a class 2b recommendation.¹⁸ It is important to notice that even in this cohort, where >90% of participants were discharged with DAPT therapy, there were still a significant number of MACE related events. In this analysis, in those without HF, black race, PVD, and ESRD were the strongest risk predictors of MACE, similar to what has been previously described in this cohort.¹⁴ Interestingly, however, these factors were not predictors of MACE in participants with HF. Rather, diabetes was the strongest predictors of MACE in those with a history of HF and PVD trended towards significance. These findings highlight the importance of risk factor identification given that even with reliable DAPT therapy, a significant number of events still occurred.

Understanding what co-morbidities are associated with an increased risk of MACE in HF patients following ACS could influence decisions about strategies for duration of DAPT following ACS as well as other potential strategies to reduce MACE following ACS in these patients. We observed that diabetes was the strongest predictors of MACE following ACS in patients with HF, similar to previous findings in other populations with ACS.^{19,20} In our population, this finding was in the setting of multivariable modeling with other risk factors, highlighting the importance of diabetes in an ACS population. Diabetes is an established risk factor for CAD events and HF has recently become a focus of therapy in the prevention of cardiovascular disease events.²¹ Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors have been shown to reduce the risk of recurrent events in individuals with established cardiovascular disease, including decreased rates of hospitalization for HF and death,²² and our findings only strengthen the case for intensive diabetes control in the setting of cardiovascular disease.

PVD was strongly associated with an increased risk of MACE in patients without HF following ACS and trended towards significance in patients with HF. DAPT therapy has been shown to reduce MACE risk in individuals with PVD, and many trials of DAPT show a substantial risk reduction in PVD subgroups.²³ Additionally, anticoagulation use reduces MACE rates in individuals with concomitant CAD and PVD. The use of rivaroxaban was shown to reduce MACE and PVD outcomes for individuals in the PVD subgroup of the Cardiovascular Outcomes for People

Using Anticoagulation Strategies (COMPASS) trial when compared to aspirin monotherapy.²⁴ In our cohort, anticoagulation use was low (16% in non-HF group and 6% in the HF group), and with PVD emerging as a predictor in multivariable modeling, highlights the importance of this comorbid condition in managing patients with ACS. These findings, coupled with our observation that PVD is a strong predictor of MACE following ACS, can guide clinicians as they determine which patients need more intensive antiplatelet and anticoagulant regimens following ACS.

However, with more intensive medical therapy, the risk of major bleeding increases. Often, the patients at highest risk for recurrent MACE events are also at highest risk of bleeding events and are therefore often not included in large randomized trials of DAPT therapy. In addition, clinical risk prediction scores, like CRUSADE,²⁵ do not discern true bleeding risk among ACS and post-PCI patients.²⁶ Additionally, patients with chronic HF are often not included in risk modeling and our study highlights the significant risk participants with HF face when PCI is used to treat ACS. In our study, we observed that individuals with HF were almost twice as likely as those without HF to experience a major bleeding event following PCI for ACS. Our findings remained statistically significant after adjustment for sociodemographic factors and other comorbidities but were no longer significant following adjustment for medication use. Interestingly, we observed that individuals with HF were 2 to 3 times more likely to be taking warfarin or apixaban following PCI for ACS than those without HF, likely a result of increased prevalence of atrial fibrillation among those with HF. This highlights the medical complexity of patients with HF and the higher rates of so-called triple therapy (DAPT plus an anticoagulant) may have contributed to our observed findings of increased bleeding risk.

In addition, renal insufficiency is an established risk factor associated with an elevated risk of major bleeding.²⁷ In our study, ESRD was a powerful predictor of bleeding following PCI for ACS in both individuals with and without HF, but was not associated with MACE in those with a history of HF. These findings suggest that shorter durations of DAPT following PCI for ACS for ESRD patients, especially in those with a history of HF who also require an anticoagulant, may be able to reduce bleeding risk without increasing MACE. This strategy deserves further investigation. When balancing the risks associated with MACE and major bleeding, it is important to note that bleeding is an independent predictor of mortality for patients undergoing PCI,²⁸ and both bleeding and MACE should be considered in decisions about medical therapy following PCI.

Our current study does have some limitations. This study is observational and from a single center, thus we are unable to establish causality. The relatively small sample size limits our power to fully assess the relationship between HF and bleeding. Additionally, we are unable to separate EFs obtained during the index encounter versus during the preceding 3 months. While this does make the study group heterogeneous, it does reflect the differential outcomes of those patients with a degree of LV dysfunction, manifested by either a low EF or clinical HF, putting them

at increased risk for MACE and major bleeding. Given that our study is observational, and despite adjusting for important past medical history and medications at discharge, unmeasured and residual confounding is always possible.

Authors' contributions

Stephen Clarkson – Conceptualization, methodology, writing – original draft, writing – review and editing, visualization; Brittain Heindl – Investigation, writing – review and editing; Anping Cai – Investigation, data curation, writing – review and editing; Mark Beasley – Methodology, formal analysis, writing – review and editing; Chrisly Dillon – Investigation, data curation, writing – review and editing; Nita Limdi – Writing – review and editing, funding acquisition, supervision; Todd M. Brown – Methodology, writing – review and editing, project administration, supervision, visualization

Disclosures

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. *Circulation* 2020;141:e139-e 596.
- Lund LH, Mancini D. Heart failure in women. *Med Clin North Am* 2004;88:1321–1345.
- Mukherjee JT, Beshansky JR, Ruthazer R, Alkofide H, Ray M, Kent D, Manning WJ, Huggins GS, Selker HP. In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial. *Cardiovasc Ultrasound* 2016;1:29–37.
- Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. *Eur J Heart Fail* 2014;16:967–976.
- Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OÖ, Savarese G, Dahlström U, Lund LH. Significance of Ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. *Circ Heart Fail* 2017;10:e00387–e00396.
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494–502.
- Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). *Eur Heart J* 2003;24:1815–1823.
- Sabbag A, Guetta V, Fefer P, Matetzky S, Gottlieb S, Meisel S, Iakobishvili Z, Blatt A, Goldenberg I, Segev A. Temporal trends and outcomes associated with major bleeding in Acute coronary syndromes: a decade-long perspective from the Acute coronary syndrome Israeli surveys 2000–2010. *Cardiology* 2015;132:163–171.
- Chin CT, Wang TY, Anstrom KJ, Zhu B, Maa JF, Messenger JC, Ryan KA, Davidson-Ray L, Zettler M, Effron MB, Mark DB, Peterson ED. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. *Am Heart J* 2011;162:844–851.
- Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, Zettler ME, Baker BA, Fonarow GC, Peterson ED. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) Study. *Circulation* 2015;132:174–181.
- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002;347:161–167.
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiwiot SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;123:2736–2747.
- Varghese T, Wenger NK. Non-ST elevation acute coronary syndrome in women and the elderly: recent updates and stones still left unturned. *F1000Res* 2018;7. F1000 Faculty Rev-1865.
- Cai A, Dillon C, Hillegass WB, Beasley M, Brott BC, Bittner VA, Perry GJ, Halade GV, Prabhu SD, Limdi NA. Risk of major adverse cardiovascular events and major hemorrhage among white and black patients undergoing percutaneous coronary intervention. *J Am Heart Assoc* 2019;8:e012874–e012885.
- Pagidipati NJ, Peterson ED. Acute coronary syndromes in women and men. *Nat Rev Cardiol* 2016;13:471–480.
- Simonsson M, Wallentin L, Alfredsson J, Erlinge D, Hellström Ångerud K, Hofmann R, Kellerth T, Lindhagen L, Ravn-Fischer A, Szummer K, Ueda P, Yndigeegn T, Jernberg T. Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDHEART registry. *Eur Heart J* 2020;41(7):833–843.
- Maldonado G, Greenland S. Simulation study of confounder-selection strategies. *Am J Epidemiol* 1993;138:923–936.
- Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *J Am Coll Cardiol* 2016;68:1082–1115.
- Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. *Diabetes Care* 2003;26:2181–2188.
- Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, Kosiborod M, Leiter LA, Lipska KJ, Newman JD, Welty FK. American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. *Circulation* 2020;141:e779–e806.
- Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial. *Circulation* 2019;139:1384–1395.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117–2128.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996;348:1329–1339.
- Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis

- BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogossova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 2018;391:219–229.
25. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can rapid risk stratification of unstable angina patients suppress Adverse outcomes with early implementation of the ACC/AHA guidelines) Bleeding score. *Circulation* 2009;119:1873–1882.
26. Chew DP, Junbo G, Parsonage W, Kerkar P, Sulimov VA, Horsfall M, Matichoss S. Perceived risk of ischemic and bleeding events in acute coronary syndrome patients (PREDICT) study investigators. Perceived risk of ischemic and bleeding events in acute coronary syndromes. *Circ Cardiovasc Qual Outcomes* 2013;6:299–308.
27. Bassand JP. Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. *Int J Cardiol* 2013;163:5–18.
28. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol* 2005;96:1200–1206.